Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported Q2 2024 financial results and provided a business update. The company is advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases, with data reports planned for 2024 and H1 2025. Key highlights include:

- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients in the CB-010 ANTLER Phase 1 trial
- $311.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into H2 2026
- Presented promising CB-010 clinical data at ASCO 2024, showing potential to rival autologous CAR-T therapies
- Advancing CB-011 for multiple myeloma and CB-012 for acute myeloid leukemia
- Planning to initiate CB-010 GALLOP Phase 1 trial for lupus by year-end 2024

Financial results show $3.5 million in licensing and collaboration revenue, $35.5 million in R&D expenses, and a net loss of $37.7 million for Q2 2024.

Positive

• Extended cash runway into H2 2026, providing at least 6 months additional funding
• Promising CB-010 clinical data presented at ASCO 2024, showing potential to rival autologous CAR-T therapies
• Advancing four clinical-stage programs with multiple data readouts expected in 2024 and 2025
• Initiated partial HLA matching strategy for CB-010, potentially improving patient outcomes
• Planning to initiate pivotal Phase 3 trial for CB-010 in H2 2025, pending positive data

Negative

• Net loss increased to $37.7 million in Q2 2024 from $29.5 million in Q2 2023
• R&D expenses increased to $35.5 million in Q2 2024 from $26.5 million in Q2 2023
• Discontinued preclinical research activities for allogeneic CAR-NK platform
• Reduced workforce by approximately 12%, incurring $0.5-$1.0 million in one-time costs

Financial Analyst

Caribou Biosciences' Q2 2024 results reveal a mixed financial picture. The company reported a $37.7 million net loss, wider than the $29.5 million loss in Q2 2023. R&D expenses increased significantly to $35.5 million, up from $26.5 million, reflecting ongoing investment in clinical trials. However, the company's cash position remains strong at $311.8 million, expected to fund operations into H2 2026. This represents a 6-month extension of their cash runway, a positive sign for investors concerned about potential dilution.

The company's focus on advancing its clinical pipeline, particularly CB-010, could drive future value. However, the increased net loss and R&D expenses highlight the cash burn rate, which investors should monitor closely. The extended cash runway provides a buffer, but Caribou will need to demonstrate clinical progress to justify the increased spending.

Oncology Researcher

Caribou's clinical progress, particularly with CB-010, is promising. The ANTLER Phase 1 trial data presented at ASCO 2024 showed potential to rival autologous CAR-T therapies, a significant benchmark in the field. The partial HLA matching strategy is innovative and could be a game-changer if it improves efficacy as suggested by retrospective analysis.

The expansion into second-line LBCL and patients who have relapsed after prior CD19-targeted therapy addresses important unmet needs. The planned pivotal Phase 3 trial in H2 2025 could be a major catalyst if data continues to be positive. The company's diversified pipeline, with trials in multiple myeloma (CB-011) and AML (CB-012), provides multiple shots on goal in hematologic malignancies. The expansion into autoimmune diseases with the GALLOP trial for lupus is an intriguing development that could open up new market opportunities.

Market Research Analyst

Caribou's focus on allogeneic CAR-T therapies positions it in a high-potential market. The allogeneic approach, if successful, could address key limitations of current autologous CAR-T therapies, including manufacturing time and cost. The company's strategy to target both hematologic malignancies and autoimmune diseases diversifies its potential market reach.

The planned initiation of a pivotal Phase 3 trial for CB-010 in H2 2025 could be a significant value inflection point. However, investors should be aware that the field is competitive, with several companies pursuing similar approaches. Caribou's success will depend on demonstrating superior efficacy or safety profiles compared to both existing therapies and competing allogeneic approaches. The company's cash runway extension provides a buffer for executing its clinical strategy, but continued progress and positive data readouts will be important for maintaining investor confidence.

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 --

-- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 --

-- $311.8 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026; cash runway extension of at least 6 months versus prior guidance --

BERKELEY, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter 2024 and reviewed recent pipeline progress.

“We are advancing our lead off-the-shelf CAR-T cell therapy, CB-010, in the ANTLER Phase 1 trial with a partial HLA matching strategy with the objective of developing an allogeneic CAR-T cell therapy that can meaningfully rival the autologous CAR-T cell therapies,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer. “We are enrolling approximately 20 second-line and 10 prior CD19 relapsed LBCL patients, and we plan to present initial data for both patient cohorts in the first half of 2025. For CB-011, we expect to report initial dose escalation data in patients with relapsed or refractory multiple myeloma by the end of this year. For CB-012, dose level 1 was cleared, and we are enrolling patients at dose level 2 in the AMpLify Phase 1 trial. We continue to focus our efforts and resources on rapidly advancing our four oncology and autoimmune disease clinical-stage programs through multiple clinical data milestones expected in 2024 and 2025.”

Clinical highlights
CB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma

• In June 2024, Caribou presented clinical data from the ongoing ANTLER Phase 1 clinical trial that indicate a single dose of CB-010 has the potential to rival the safety and efficacy of approved autologous CAR-T cell therapies. The clinical results were presented during a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
• At ASCO, Caribou presented data on the first 46 patients enrolled in ANTLER. Three dose levels of CB-010 were evaluated (40x10⁶, 80x10⁶, and 120x10⁶ CAR-T cells) and 80x10⁶ CAR-T cells was selected as the recommended Phase 2 dose (RP2D). In dose escalation, 16 patients with multiple subtypes of aggressive relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) were enrolled, and, in dose expansion, 30 patients with second-line large B cell lymphoma (2L LBCL) were enrolled. As of the April 1, 2024 data cutoff date, results demonstrated:
  • CB-010 was generally well tolerated. No Grade 3 or higher cytokine release syndrome (CRS) and no graft-versus-host disease (GvHD) was observed.
  • A retrospective analysis of all patient data demonstrated that patients who received a dose of CB-010 manufactured from a healthy donor who shared four or more matching human leukocyte antigen (“HLA”) alleles with the patient (referred to as partial HLA matching) showed the potential for improved efficacy.
  • Pharmacokinetic (PK) data showed that partial HLA matching correlated with increased CAR-T cell expansion and persistence. Pharmacodynamic (PD) data showed extended B cell aplasia and rapid recovery of patients’ endogenous T and NK cells.
• Based on these data, Caribou has begun dosing a cohort of approximately 20 2L LBCL patients to prospectively confirm that partial HLA matching may improve patient outcomes.
• Caribou also is enrolling a cohort of up to 10 patients who have relapsed following any prior CD19-targeted therapy in a proof-of-concept cohort in this population of unmet need. This cohort will also incorporate partial HLA matching between donors and patients.
• Caribou plans to initiate a pivotal Phase 3 trial in the second half of 2025, should data confirm improved outcomes for patients receiving a partially HLA matched dose of CB-010 and following agreement with the FDA on a pivotal trial design.

CB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for lupus

• Caribou plans to initiate the GALLOP Phase 1 clinical trial to evaluate a single infusion of CB-010 in adult patients with lupus nephritis (LN) and extrarenal lupus (ERL). The trial will incorporate partial HLA matching between donors and patients.
• Caribou plans to initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.

CB-011, a clinical-stage allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma

• Caribou is enrolling patients with relapsed or refractory multiple myeloma (r/r MM) in the dose escalation portion of the ongoing CaMMouflage Phase 1 clinical trial.
• Caribou plans to present initial dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial by year-end 2024.

CB-012, a clinical-stage allogeneic anti-CLL-1 CAR-T cell therapy for acute myeloid leukemia

• In June 2024, a poster was presented at ASCO on the AMpLify Phase 1 trial design for CB-012 in adults with relapsed or refractory acute myeloid leukemia (r/r AML).
• Caribou is enrolling patients with r/r AML in the dose escalation portion of the ongoing AMpLify Phase 1 clinical trial. Enrollment has concluded for dose level 1 (25x10⁶ CAR-T cells, N=3) and patients are being enrolled at dose level 2 (75x10⁶ CAR-T cells).

Corporate updates
Appointed autoimmune expert to Caribou’s scientific advisory board

• In July 2024, Terri Laufer, MD, was appointed to Caribou’s scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Medical Center and Philadelphia VA Medical Center.
  

Extended cash runway into H2 2026

• In July 2024, Caribou discontinued the preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by approximately 12%. The workforce reduction, together with other cost containment measures, are expected to extend the cash runway by at least 6 months, into H2 2026. The Company will incur approximately $0.5 million to $1.0 million in one-time costs consisting primarily of cash severance costs, benefits, and transition support services for impacted employees.
  

Anticipated milestones

• CB-010 ANTLER: Caribou plans to present initial data from both the additional HLA-matched 2L and prior CD19 relapsed LBCL patient cohorts in H1 2025. Caribou plans to initiate a pivotal Phase 3 clinical trial in H2 2025 should data confirm improved outcomes for patients receiving a partially HLA matched dose of CB-010.
• CB-010 GALLOP: Caribou plans to initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.
• CB-011 CaMMouflage: Caribou plans to present initial dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial by year-end 2024.
• CB-012 AMpLify: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Second quarter 2024 financial results
Cash, cash equivalents, and marketable securities: Caribou had $311.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024, compared to $372.4 million as of December 31, 2023. Caribou expects these cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into H2 2026.

Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.5 million for the three months ended June 30, 2024, compared to $3.8 million for the same period in 2023. The decrease was primarily due to the now-terminated AbbVie Collaboration and License Agreement, partially offset by an increase in revenue recognized under the Information Rights Agreement Caribou entered into with Pfizer on June 29, 2023. Licensing and collaboration revenue for the three months ended June 30, 2024, includes $1.6 million in a one-time receipt of non-cash equity consideration from one of Caribou’s licensees.

R&D expenses: Research and development expenses were $35.5 million for the three months ended June 30, 2024, compared to $26.5 million for the same period in 2023. The increase was primarily due to costs to advance pipeline programs, including the CB-010 ANTLER, CB-011 CaMMouflage, and CB-012 AMpLify Phase 1 clinical trials; personnel-related expenses, including stock-based compensation, due to headcount increases; and facilities and other allocated expenses.

G&A expenses: General and administrative expenses were $11.5 million for the three months ended June 30, 2024, compared to $10.1 million for the same period in 2023. The increase was primarily due to personnel-related expenses, including stock-based compensation, due to headcount increases, and legal expenses and other service-related expenses. These increases were partially offset by a decrease in patent prosecution and maintenance fees.

Net loss: Caribou reported a net loss of $37.7 million for the three months ended June 30, 2024, compared to $29.5 million for the same period in 2023.

About CB-010
CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform, and it is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 clinical trial and will be evaluated in patients with lupus nephritis (LN) and extrarenal lupus (ERL) in the GALLOP Phase 1 clinical trial. In the ANTLER clinical trial, Caribou is enrolling second-line (2L) patients with large B cell lymphoma (LBCL) comprised of different subtypes of aggressive r/r B-NHL (DLBCL NOS, PMBCL, HGBL, tFL, and tMZL) who have never received prior CD19-targeted therapy as well as LBCL patients who have relapsed on a prior CD19-targeted therapy. To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve activity against diseases by limiting premature CAR-T cell exhaustion. CB-010 is also, to Caribou’s knowledge, the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the 2L LBCL setting and, for r/r B-NHL, CB-010 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations by the FDA. Additional information on the ANTLER trial (NCT04637763) can be found at clinicaltrials.gov.

About CB-011
CB-011 is a product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage Phase 1 trial. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy engineered using Cas12a chRDNA genome-editing technology. To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to improve antitumor activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. CB-011 has been granted Fast Track and orphan drug designations by the FDA. Additional information on the CaMMouflage trial (NCT05722418) can be found at clinicaltrials.gov.

About CB-012
CB-012 is a product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in the AMpLify Phase 1 clinical trial in patients with relapsed or refractory acute myeloid leukemia (r/r AML). CB-012 is an anti-CLL-1 CAR-T cell therapy engineered with five genome edits, enabled by Caribou’s patented next-generation CRISPR technology platform, which uses Cas12a chRDNA genome editing to significantly improve the specificity of genome edits. To Caribou’s knowledge, CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption, through a PD-1 knockout, and immune cloaking, through a B2M knockout and B2M–HLA-E fusion protein insertion; both armoring strategies are designed to improve antitumor activity. Caribou has exclusively in-licensed from Memorial Sloan Kettering Cancer Center (MSKCC) in the field of allogeneic CLL-1-targeted cell therapy a panel of fully human scFvs targeting CLL-1, from which the company has selected a scFv for the generation of the company’s CAR. Additional information on the AMpLify trial (NCT06128044) can be found at clinicaltrials.gov.

About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of clinical-stage off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to Caribou’s strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs, including its expectations relating to (i) the timing of reporting additional dose expansion data in its ANTLER Phase 1 clinical trial for CB-010, including data from both additional HLA-matched 2L LBCL and prior CD19 cohorts, and the timing of an ANTLER pivotal Phase 3 clinical trial; (ii) the timing of and updates from its CaMMouflage Phase 1 clinical trial for CB-011 and expectations regarding the timing of presenting the initial dose escalation data; (iii) the timing of and updates from its AMpLify Phase 1 clinical trial for CB-012; (iv) the timing of and updates from its GALLOP Phase 1 clinical trial for CB-010 in patients with LN and ERL; (v) the anticipated costs associated with the workforce reduction, including specific categories of costs and future cash expenditures and the timing of when the reduction is expected to be completed and the anticipated costs recognized; and (vi) its expected funding runway of cash, cash equivalents, and marketable securities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of Caribou’s current and future research and development programs, preclinical studies, and clinical trials; and the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available; the risk that preclinical study results observed will not be borne out in human patients or different conclusions or considerations are reached once additional data have been received and fully evaluated; the ability to obtain key regulatory input and approvals; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Caution should be exercised when interpreting results from separate trials involving other CAR-T cell therapies. The results of other CAR-T cell therapies presented or referenced in this press release have been derived from publicly available reports of clinical trials not conducted by Caribou, and Caribou has not performed any head-to-head trials comparing any of these other CAR-T cell therapies with CB-010. As such, the results of these other clinical trials may not be comparable to clinical results for CB-010. The design of these other clinical trials varies in material ways from the design of the ANTLER clinical trial for CB-010, including with respect to patient populations, follow-up times, clinical trial phases, and subject characteristics. As a result, cross-trial comparisons may have no interpretive value on Caribou’s existing or future clinical results. For further information and to understand these material differences, you should read the reports for the other CAR-T cell therapy clinical trials and the sources included in Caribou’s corporate presentations on its website.

Caribou Biosciences, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited)
	June 30, 2024				December 31, 2023
Cash, cash equivalents, and marketable securities	$	311,773			$	372,404
Total assets		372,938				432,209
Total liabilities		62,474				63,808
Total stockholders' equity		310,464				368,401
Total liabilities and stockholders' equity	$	372,938			$	432,209

Caribou Biosciences, Inc. Condensed Consolidated Statement of Operations (in thousands, except share and per share data) (unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Licensing and collaboration revenue	$	3,464			$	3,755			$	5,893			$	7,257
Operating expenses:
Research and development		35,480				26,503				69,268				52,212
General and administrative		11,485				10,120				26,128				19,029
Total operating expenses		46,965				36,623				95,396				71,241
Loss from operations		(43,501	)			(32,868	)			(89,503	)			(63,984	)
Other income (expense):
Change in fair value of equity securities		(102	)			22				(102	)			7
Change in fair value of the MSKCC success payments liability		1,795				279				2,098				534
Other income - net		4,111				3,048				8,576				5,880
Total other income (expense)		5,804				3,349				10,572				6,421
Net loss		(37,697	)			(29,519	)			(78,931	)			(57,563	)
Other comprehensive (loss) income:
Net unrealized (loss) gain on available-for-sale marketable securities, net of tax		3				(406	)			(349	)			382
Net comprehensive loss	$	(37,694	)		$	(29,925	)		$	(79,280	)		$	(57,181	)
Net loss per share, basic and diluted	$	(0.42	)		$	(0.48	)		$	(0.88	)		$	(0.94	)
Weighted-average common shares outstanding, basic and diluted		90,340,932				61,417,934				89,821,935				61,302,863

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

FAQ

What were Caribou Biosciences' (CRBU) Q2 2024 financial results?

Caribou Biosciences reported $3.5 million in licensing and collaboration revenue, $35.5 million in R&D expenses, and a net loss of $37.7 million for Q2 2024. The company had $311.8 million in cash, cash equivalents, and marketable securities as of June 30, 2024.

What clinical programs is Caribou Biosciences (CRBU) currently advancing?

Caribou Biosciences is advancing four clinical-stage programs: CB-010 for B cell non-Hodgkin lymphoma and lupus, CB-011 for multiple myeloma, and CB-012 for acute myeloid leukemia. The company plans to present data from these programs throughout 2024 and 2025.

When does Caribou Biosciences (CRBU) expect to initiate a pivotal Phase 3 trial for CB-010?

Caribou Biosciences plans to initiate a pivotal Phase 3 trial for CB-010 in the second half of 2025, pending confirmation of improved outcomes for patients receiving a partially HLA matched dose and agreement with the FDA on the trial design.

How long is Caribou Biosciences' (CRBU) current cash expected to fund operations?

Caribou Biosciences expects its current cash, cash equivalents, and marketable securities of $311.8 million to fund its operating plan into the second half of 2026, extending the cash runway by at least 6 months compared to previous guidance.